Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-10-18
2011-11-29
Landsman, Robert (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S001100, C530S351000
Reexamination Certificate
active
08067375
ABSTRACT:
Methods of treating a demyelinating disorder using inhibitors of the lymphotoxin pathway.
REFERENCES:
patent: 3773919 (1973-11-01), Boswell et al.
patent: 4338397 (1982-07-01), Gilbert et al.
patent: 4485045 (1984-11-01), Regen
patent: 4544545 (1985-10-01), Ryan et al.
patent: 4758549 (1988-07-01), Mitsuhashi et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4822605 (1989-04-01), Powell
patent: 4849509 (1989-07-01), Thurin et al.
patent: 4959457 (1990-09-01), Bringman
patent: 5082783 (1992-01-01), Ernst et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5541087 (1996-07-01), Lo et al.
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 5661004 (1997-08-01), Browning et al.
patent: 5670149 (1997-09-01), Browning et al.
patent: 5721121 (1998-02-01), Etcheverry et al.
patent: 5726039 (1998-03-01), Oppenheim et al.
patent: 5795964 (1998-08-01), Browning et al.
patent: 5856179 (1999-01-01), Chen et al.
patent: 5925351 (1999-07-01), Browning et al.
patent: 5976833 (1999-11-01), Furukawa et al.
patent: 6312691 (2001-11-01), Browning et al.
patent: 6403087 (2002-06-01), Browning et al.
patent: 6669941 (2003-12-01), Browning et al.
patent: 7001598 (2006-02-01), Browning et al.
patent: 7030080 (2006-04-01), Browning et al.
patent: 7060667 (2006-06-01), Browning et al.
patent: 7255854 (2007-08-01), Browning et al.
patent: 7294481 (2007-11-01), Fung
patent: 7309492 (2007-12-01), Browning et al.
patent: 7427403 (2008-09-01), Browning et al.
patent: 7452530 (2008-11-01), Browning et al.
patent: 7459537 (2008-12-01), Browning et al.
patent: 2002/0001585 (2002-01-01), Browning et al.
patent: 2002/0039580 (2002-04-01), Browning et al.
patent: 2002/0197254 (2002-12-01), Browning et al.
patent: 2004/0058394 (2004-03-01), Garber et al.
patent: 2004/0198635 (2004-10-01), Browning et al.
patent: 2005/0037003 (2005-02-01), Browning et al.
patent: 2005/0281811 (2005-12-01), Browning et al.
patent: 2006/0104971 (2006-05-01), Garber et al.
patent: 2006/0134102 (2006-06-01), LePage et al.
patent: 2006/0222644 (2006-10-01), Garber et al.
patent: 2006/0280722 (2006-12-01), Browning et al.
patent: 2007/0116668 (2007-05-01), Browning et al.
patent: 2007/0154476 (2007-07-01), Browning et al.
patent: 2008/0076155 (2008-03-01), Fung
patent: 2008/0219967 (2008-09-01), Browning et al.
patent: 3218121 (1983-11-01), None
patent: 0058481 (1982-08-01), None
patent: 0367575 (1990-05-01), None
patent: 0496973 (1992-08-01), None
patent: 0509553 (1992-10-01), None
patent: 0608532 (1994-08-01), None
patent: 0873998 (1998-10-01), None
patent: WO-91/00347 (1991-01-01), None
patent: WO-92/00329 (1992-01-01), None
patent: WO-94/04679 (1994-03-01), None
patent: WO-94/06476 (1994-03-01), None
patent: WO-94/13808 (1994-06-01), None
patent: WO-96/01121 (1996-01-01), None
patent: WO-96/22788 (1996-08-01), None
patent: WO-96/23071 (1996-08-01), None
patent: WO-97/03678 (1997-02-01), None
patent: WO-97/03687 (1997-02-01), None
patent: WO-97/04658 (1997-02-01), None
patent: WO-97/41895 (1997-11-01), None
patent: WO-98/17313 (1998-04-01), None
patent: WO-98/18928 (1998-05-01), None
patent: WO-98/25967 (1998-06-01), None
patent: WO-99/53059 (1999-10-01), None
patent: WO-2007/146414 (2007-12-01), None
Gommerman JL, et al. J. Clin. Invest. 112(5):755-767, Sep. 1, 2003.
Lin X et al., International Immunology 15(8):955-962, 2003.
Plant SR, et al. Presentation No. 213.2, Neuroscience Meeting Planner, New Orleans, LA, Society for Neuroscience, 2003.
Abe, Yasuhito et al., “Expression of Membraine-associated Lymphotoxin/Tumor Necrosis Factor-β on Human Lymphokine-activated Killer Cells,”Jpn. J. Cancer Res., vol. 82:23-26 (1991).
Abe, Yasuhito et al., “Studies of Membrane-Associated and Soluble (Secreted) Lymphotoxin in Human Lymphokine-Activated T-Killer Cells in Vitro,”Lymphokine and Cytokine Research, vol. 11(2):115-121 (1992).
Acharya, S.K. et al., “A preliminary open trial on interferon stimulator (SNMC) derived fromGlycyrrhiza glabrain the treatment of subacute hepatic failure,”Indian J. Med. Res. [B], vol. 98:69-74 (1993).
Aebersold, Ruedi H. et al., “Internal amino acid sequence analysis of proteins separated by one- or two-dimensional gel electrophoresis after in situ protease digestion on nitrocellulose,”Proc. Natl. Acad. Sci. USA, vol. 84:6970-6974 (1987).
Aggarwal, Bharat B. et al., “Human Lymphotoxin,”The Journal of Biological Chemistry, vol. 259(1):686-691 (1984).
Aggarwal, Bharat B. et al., “Primary Structure of Human Lymphotoxin Derived from 1788 Lymphoblastoid Cell Line,”The Journal of Biological Chemistry, vol. 260(4):2334-2344 (1985).
Aggarwal, Bharat B. et al., “Tumor necrosis factors: Developments during the last decade,”Eur. Cytokine Netw., vol. 7(2):93-124 (1996).
Akashi, Makoto et al., “Lymphotoxin: Stimulation and Regulation of Colony-Stimulating Factors in Fibroblasts,”Blood, vol. 74(7):2383-2390 (1989).
Alderson, Mark R. et al., “Molecular and biological characterization of human 4-1BB and its ligand,”Eur. J. Immunol., vol. 24:2219-2227 (1994).
Alderson, Mark R. et al., “Regulation of apoptosis and T cell activation by Fas-specific mAb,”International Immunology, vol. 6(11):1799-1806 (1994).
Alexopoulou, Lena et al., “Immunoregulatory Activities of Transmembrane TNF Revealed in Transgenic and Mutant Mice,”6th international TNF Congress, p. 228, No. 110 (1996).
Alimzhanov, Marat B. et al., “Abnormal development of secondary lymphoid tissues in lymphotoxin β-deficient mice,”Proc. Natl. Acad. Sci. USA, vol. 94:9302-9307 (1997).
Amiri, Payman et al., “Tumour necrosis factor α restores granulomas and induces parasite egg-laying in schistosome-infected SCID mice,”Nature, vol. 356:604-607 (1992).
Anderson, W. French, “Human gene therapy,”Nature, vol. 392:25-30 (1998).
Andersson, Ulf et al., “Characterization of individual tumor necrosis factor α- and β-producing cells after polyclonal T cell activation,”Journal of Immunological Methods, vol. 123:233-240 (1989).
Andrews, Janet S. et al., “Characterization of the Receptor for Tumor Necrosis Factor (TNF) and Lymphotoxin (LT) on Human T Lymphocytes, TNF and LT Differ in Their Receptor Binding Properties and the Induction of MHC Class I Proteins on a Human CD4+ T Cell Hybridoma,”The Journal of Immunology, vol. 144(7):2582-2591 (1990).
Androlewicz, Matthew J. et al., “Lymphotoxin Is Expressed as a Hetermeric Complex with a Distinct 33-kDa Glycoprotein on the Surface of an Activated Human T Cell Hybridoma,”The Journal of Biological Chemistry, vol. 267(4):2542-2547 (1992).
Armitage, Richard J. et al., “Molecular and biological characterization of a murine ligand for CD40,”Nature, vol. 357:80-82 (1992).
Arulanandam, Antonio R.N. et al., “A Soluble Multimeric Recombinant CD2 Protein Identifies CD48 as a Low Affinity Ligand for Human CD2: Divergence of CD2 Ligands during the Evolution of Humans and Mice,”J. Exp. Med., vol. 177:1439-1450 (1993).
Ashkenazi, Avi et al., “Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin,”Proc. Natl. Acad. Sci. USA, vol. 88:10535-10539 (1991).
Badenhoop, K. et al., “TNF-α gene polymorphisms in Type 1 (insulin-dependent) diabetes mellitus,”Diabetologia, vol. 32:445-448 (1989).
Baens, Mathijs et al., “Construction and Evaluation of a hncDNA Library of Human 12p Transcribed Sequences Derived from a Somatic Cell Hybrid,”Genomics, vol. 16:214-218 (1993).
Banks, Theresa A. et al., “Lymphotoxin-α-Deficient Mice,”The Journal of Immunology, vol. 155:1685-1693 (1995).
Banner, David W. et al., “Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNFβ Complex: Implications for TNF Receptor Activation,”Cell, vol. 73:431-445 (1993).
Barnetson, “Hypersensitivity—Type IV,&#
Browning Jeffrey L.
Ting Jenny P-Y
Biogen Idec MA Inc.
Landsman Robert
Nelson Mullins Riley & Scarborough LLP
University of North Carolina at Chapel Hill
Williams Megan E.
LandOfFree
Treatment of demyelinating disorders with soluble... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of demyelinating disorders with soluble..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of demyelinating disorders with soluble... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4311771